Indira IVF Forays Into Diagnostics Business by Launching Indira Pathlabs

Indira PathLabs_Logo

21 December 2022, Delhi: Indira IVF, India’s largest fertility treatments chain, has announced its entry into diagnostics by offering pathology tests uniquely catering to the needs of women and child. The organisation has inaugurated its state-of-the-art laboratories in Lucknow, New Delhi, Patna and Mumbai, and aims to launch a total of 30+ pathology laboratories in strategic geographies by FY24 and two super speciality labs in Mumbai and Delhi.

Indira PathLabs will leverage Indira IVF’s already established network of 114 centres in the country. In the Phase 1 of expansion in FY23, it will gradually expand services to all major geographies where it has a robust presence including Lucknow, Patna, New Delhi, Mumbai, Pune, Udaipur, Jaipur, Varanasi, Kolkata, Ranchi, Bhubaneswar, and Bengaluru to name a few. The company aspires to launch its pathology offerings by way of fully-equipped, independent laboratories and harnessing the benefits of automation.

Commenting on the addition of Indira PathLabs, Dr Nitiz Murdia – Managing Director & Co-Founder of Indira IVF said, “At Indira IVF, we have always been determined to provide solutions under the same roof and we aspire to do the same with Indira PathLabs. With this integration, we will be able to address the full spectrum of diagnostics needs of women from the time of planning for a pregnancy to conception and delivery. Regular testing for different vitals becomes essential on this journey and we hope to help aspiring mothers through recommendations of our gynaecologist partners.

“Furthermore, genetic testing is an essential tool to ascertain the future child’s health and check for the presence of any genetic anomalies. In this regard, in addition to our pathology services, we also seek to introduce two genetic testing laboratories in the country that can perform highly specialised tests required for the prediction of such genetic anomalies in the child conceived,” he added.

Addressing the requirement of women and child diagnostic needs, Dr Kshitiz Murdia – CEO & Co-Founder of Indira IVF said, “Healthcare has become a priority for everyone in today’s world. As a leading IVF chain, we feel there is still a huge dearth of quality diagnostics specifically for women and child related tests that doctors and patients can trust. We aim to answer this gap with a range of high quality diagnostic tests for accurate and timely results. Also, given the requirement for our own IVF treatments, it is a strategic decision to launch specialty pathology laboratories which will not only meet the requirements of our patients to complete the whole cycle with us but will also answer the need of trusted diagnostics care for all. 

Backed by an array of trusted clinical offerings, Indira PathLabs will provide accessible, high-quality diagnostics services and hopes to bridge the existing gaps in the market specifically related to conception and the needs of women and their child. The organisation aspires to incorporate more than 1000 tests to fully encompass the gamut of diagnostic investigations required on the journey of conception and leading to a healthy child’s birth.

Leave a Reply

Your email address will not be published. Required fields are marked *